Illumina investment push


Gene sequencing company Illumina has struck a $450 million (£280 million) deal to buy privately owned US firm Verinata Health, which specialises in non-invasive tests for early identification of foetal chromosomal abnormalities.

The deal follows the collapse of Roche’s $5.7 billion hostile bid for Illumina in early 2012 – which the company rejected. It also follows Illumina’s acquisition of BlueGnome, a University of Cambridge spinout that has developed a test for counting chromosomes in a cell.

Illumina will pay $350 million up front, plus up to $100 million in milestone payments.

 


Related Content

Rapid DNA sequencing cleared for the clinic

21 November 2013 Business

news image

Illumina’s ‘next-generation’ MiSeqDx platform gets US approval

Sequencing in the fast lane

25 July 2012 Premium contentFeature

news image

Phillip Broadwith gets up to speed with the latest developments in DNA sequencing technology

Most Read

Cocaine users sweat over fingerprint analysis

19 May 2015 Research

news image

Surface mass spectrometry quickly detects cocaine metabolites in fingerprints

Opiate-producing yeast raises spectre of 'home-brewed heroin'

18 May 2015 News and Analysis

news image

Warnings that completion of final steps in opiate biosynthesis could be a double-edged sword

Most Commented

The nuclear danger of iodine

20 May 2015 Comments

news image

It may not be an element you think of as problematic. But, as Mark Foreman explains, iodine causes very complicated problems ...

All set for chemistry

15 May 2015 Feature

news image

Chemistry sets through the years have both weathered and reflected many changes in science and society, as Philip Ball discov...